Author:
Kalyan Ram Bhamidimarri,Frank Czul,Adam Peyton,Cynthia Levy,Maria Hernandez,Lennox Jeffers,David Roth,Eugene Schiff,Christopher O’Brien,Paul Martin
Reference15 articles.
1. EASL recommendations on treatment of hepatitis C 2014;J Hepatol,2014
2. AASLD, IDSA Recommendations for testing, managing and treating Hepatitis C. (accessed March 4th 2015).
3. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment naıve patients with genotypes 1, 2, and 3 hepatitis C infection: a randomized, double-blind, phase 2 trial;Lawitz;Lancet Infect Dis,2013
4. Anti-viral efficacy and pharmacokinetics (PK) of Sofosbuvir (SOF) in patients with severe renal impairment;Gane;Hepatology,2014
5. Pharmacokinetics, safety and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects;Denning;Antimicrob Agents Chemother,2013
Cited by
94 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献